WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
SJIF Impact Factor 8.453
Volume 14, Issue 19, 255-277. Review Article ISSN 2277–7105

ANTIMICROBIAL ACTIVITY OF EUGENOL AND CINNAMALDEHYDE AGAINST METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) IN ERBIL, KURDISTAN, IRAQ

Khawaja Shakeel Ahmed[1*], Merza H. Homady[2]

[1]Department of Medical Microbiology, Cihan University-Erbil, Kurdistan Region, Iraq.

[2]Department of Biomedical Sciences, Cihan University-Erbil, Kurdistan Region, Iraq.

Article Received on
12 August 2025,

Revised on 02 Sept. 2025,
Accepted on 23 Sept. 2025

https://doi.org/10.5281/zenodo.17214204

***Corresponding Author**
Dr. Khawaja Shakeel Ahmed
Department of Medical Microbiology, Cihan University-Erbil, Kurdistan Region, Iraq.

ABSTRACT

Methicillin-resistant Staphylococcus aureus (MRSA) is recognized as a critical global health threat due to its high prevalence in both hospital and community settings and its remarkable resistance to multiple classes of antibiotics. MRSA infections can range from superficial skin and soft tissue infections to severe systemic illnesses, including sepsis, pneumonia, and endocarditis, often leading to increased morbidity, mortality, and healthcare costs. The growing emergence of multidrug-resistant MRSA strains has created an urgent need for alternative antimicrobial strategies beyond conventional antibiotics. Natural phytochemicals, particularly Eugenol and Cinnamaldehyde, have emerged as promising candidates in this context. Eugenol, a phenolic compound predominantly found in clove oil, and Cinnamaldehyde, an aromatic aldehyde derived from cinnamon bark, exhibit potent antimicrobial activity through multiple mechanisms, including disruption of bacterial cell membranes, inhibition of essential enzymatic functions, induction of oxidative stress, and suppression of biofilm formation. These multifaceted actions not only inhibit bacterial growth but also reduce virulence and resistance potential. This review comprehensively synthesizes recent studies (2018–2025) investigating the antimicrobial efficacy of Eugenol and Cinnamaldehyde, with a particular focus on MRSA isolates collected from diverse hospital settings in Erbil, Kurdistan, Iraq. It explores the potential synergistic interactions of these phytochemicals with conventional antibiotics, which may enhance therapeutic effectiveness while mitigating the development of resistance. The article also

discusses challenges associated with clinical translation, including variability in extract composition, bioavailability, safety, and delivery methods, and highlights future research directions such as in vivo studies, advanced formulations, and clinical trials. Placeholders for figures and tables are included to depict chemical structures, mechanisms of action, MIC/MBC data, workflow diagrams, and regional epidemiological patterns, providing a comprehensive framework for understanding the role of Eugenol and Cinnamaldehyde in combating MRSA infections.

KEYWORDS: MRSA, Eugenol, Cinnamaldehyde, Antimicrobial, Phytochemicals, Kurdistan, Hospital-acquired infections.

1. INTRODUCTION: The Global Threat of MRSA

Methicillin-resistant Staphylococcus aureus (MRSA) is a Gram-positive bacterium that poses a significant threat to public health worldwide. It is responsible for a broad spectrum of infections, ranging from relatively minor skin and soft tissue infections to severe, life-threatening conditions including pneumonia, bacteremia, endocarditis, osteomyelitis, and sepsis (Lowy, 2003). MRSA infections are associated with high morbidity and mortality, prolonged hospital stays, and increased healthcare costs, making them a major burden on healthcare systems. Recognizing its global impact, the World Health Organization (WHO, 2021) has classified MRSA as a high-priority pathogen due to its multidrug resistance and widespread prevalence.

1.1 Epidemiological Significance

The epidemiology of MRSA is complex, with distinct differences observed between hospital-acquired MRSA (HA-MRSA) and community-acquired MRSA (CA-MRSA). HA-MRSA strains are typically associated with invasive infections in immunocompromised individuals, prolonged hospitalization, and higher mortality rates. In contrast, CA-MRSA strains more commonly cause skin and soft tissue infections but are increasingly implicated in severe systemic infections (Rai et al., 2020).

The prevalence of MRSA varies regionally, influenced by factors such as antibiotic prescribing practices, infection control measures, and healthcare infrastructure. In Erbil, Kurdistan, Iraq, clinical studies have reported MRSA prevalence rates ranging from 25–40% among hospital isolates (Al-Khafaji et al., 2022). This high prevalence underscores the critical need for alternative or adjunct antimicrobial strategies, particularly in regions with

limited access to advanced antibiotics or where resistance trends are escalating. Understanding the regional epidemiology of MRSA is essential for the development of effective treatment protocols and targeted infection control measures.

1.2 Antibiotic Resistance Mechanisms

MRSA has evolved an array of sophisticated resistance mechanisms that enable it to survive exposure to multiple antibiotic classes. Key strategies include.

- **Alteration of penicillin-binding proteins (PBP2a):** The mecA gene encodes PBP2a, which has a low affinity for β-lactam antibiotics, rendering these drugs largely ineffective against MRSA.
- **Efflux pumps:** These membrane proteins actively expel antibiotics from bacterial cells, reducing intracellular drug concentrations and limiting efficacy.
- **Enzymatic degradation:** MRSA produces enzymes such as β-lactamases that chemically inactivate antibiotics before they can reach their targets.
- **Biofilm formation:** MRSA can form structured bacterial communities known as biofilms, which provide a protective environment that enhances resistance to antimicrobial agents and host immune responses.

The multiplicity and redundancy of these resistance mechanisms have stimulated considerable interest in exploring natural phytochemicals, such as Eugenol and Cinnamaldehyde, as potential antimicrobial agents. These compounds have the unique ability to target multiple bacterial pathways simultaneously, disrupting membrane integrity, inhibiting essential enzymes, inducing oxidative stress, and preventing biofilm formation, thereby offering a multifaceted approach to combat MRSA infections.

2. Phytochecmicals Of Interest

The search for alternative antimicrobial agents has increasingly focused on naturally derived phytochemicals due to their diverse chemical structures and multifaceted biological activities. Among these, Eugenol and Cinnamaldehyde have emerged as prominent candidates for combating multidrug-resistant pathogens such as MRSA. Their broad-spectrum antimicrobial properties, coupled with multiple mechanisms of action, make them particularly attractive for potential therapeutic applications.

2.1 Eugenol

Eugenol (4-allyl-2-methoxyphenol) is a naturally occurring phenolic compound predominantly found in clove oil (Syzygium aromaticum), and to a lesser extent in cinnamon, basil, and bay leaves (Rather et al., 2016). Traditionally, Eugenol has been used for its analgesic, anti-inflammatory, antiseptic, and antioxidant properties in folk and conventional medicine. More recently, scientific investigations have highlighted its potent antimicrobial activity against a wide range of pathogens, including antibiotic-resistant bacterial strains such as MRSA.

Mechanisms of Antimicrobial Action

- **Membrane Disruption:** Eugenol interacts with the lipid bilayer of bacterial cell membranes, increasing permeability and causing leakage of vital intracellular components such as ions, ATP, and nucleic acids. This destabilization compromises cell integrity and ultimately leads to bacterial death.
- **Enzyme Inhibition:** Eugenol interferes with key bacterial metabolic enzymes, reducing energy production and disrupting essential cellular processes.
- **Quorum Sensing Inhibition:** By impeding bacterial communication pathways, Eugenol inhibits quorum sensing, thereby preventing coordinated pathogenic behaviors such as virulence factor production and biofilm formation.
- **Anti-Biofilm Activity:** Eugenol effectively reduces bacterial adhesion and inhibits the development and maturation of biofilms, structures that provide protection against host defenses and antibiotics.



Eugenol

Fig.1: Chemical structure of Eugenol.

Table 1: Summary of studies reporting MIC and MBC of Eugenol against MRSA (2018–2025).

Study (Year) / Source	MRSA Strain (if stated)	MIC (µg/mL or %)	MBC (µg/mL or %)	Notes
Kim et al. (2023) — Raman Spectroscopy study (PMC)	Clinical MRSA strains	**416–1024 µg/mL**	Not reported	Provided MIC range; MBC not specified.
El-Far et al. (2021): Biofilm-focused study (PubMed)	Egyptian clinical MRSA isolates	**0.01%–3.125% (v/v)**	Not reported	Percentage dilution used for MIC in biofilm context.
Hartman et al. (2025): EOCs panel including Eugenol (IJPSR)	MRSA ATCC 43300	**8.33 mg/mL**	**8.33 mg/mL**	Both MIC and MBC are identical, indicating bactericidal activity.
Bai (2023): Clove essential oil (contains Eugenol) (PMC)	S. aureus (not MRSA-specific)	**0.26 mg/mL**	**0.52 mg/mL**	Useful for comparison; MRSA-specific values not provided.

2.2 Cinnamaldehyde

Cinnamaldehyde, the primary bioactive compound in cinnamon bark essential oil (Cinnamomum verum and Cinnamomum cassia), is an aromatic aldehyde responsible for the characteristic flavor and aroma of cinnamon. In addition to its widespread use in culinary applications, Cinnamaldehyde has demonstrated potent antimicrobial properties against a broad spectrum of pathogens, including Gram-positive and Gram-negative bacteria, fungi, and drug-resistant strains such as MRSA (Oon et al., 2015).

Mechanisms of Antimicrobial Action

- **Cell Wall Damage:** Cinnamaldehyde disrupts the integrity of bacterial cell walls and membranes, causing leakage of intracellular contents and impairing essential structural and metabolic functions.
- **Enzyme Modulation:** It interferes with bacterial enzymatic activity, reducing the ability of pathogens to synthesize key cellular components and sustain metabolic processes.
- **Biofilm Inhibition:** Cinnamaldehyde suppresses MRSA biofilm formation by interfering with quorum sensing pathways, thereby enhancing susceptibility to antibiotics and host immune responses.
- **Suppression of Virulence Factors:** The compound decreases the expression of toxins, adhesins, and other virulence determinants, weakening the pathogenic potential of MRSA.



Fig 2: Chemical structure of Cinnamaldehyde.

Table 2: MIC and MBC of Cinnamaldehyde against MRSA isolates from different studies.

Study / Year	MRSA Strain or Context	MIC	MBC	Notes
Firmino et al. (2018) (Wiley Online Library)	S. aureus (not MRSA-specific)	0.25 mg/mL	0.50 mg/mL	Provides comparative context; not MRSA-exclusive
PMC study (2021) (PMC)	MRSA strain 1037 (weak biofilm)	0.06 mg/mL	0.06 mg/mL	Planktonic cells. Same high-level bactericidal effect
PMC study (2021) (PMC)	MRSA strain 27887 (strong biofilm)	0.24 mg/mL	0.48 mg/mL	Planktonic cells; biofilm conditions detailed
Various in vitro synergy data (PMC)	MRSA strains combined with antibiotics	31.25–62.5 µg/mL (1/8–1/4 MIC equivalent)	–	Reflects effective synergistic use with antibiotics
Clinical data (China, ROS inhibition) (PubMed)	MRSA isolates (biofilm context)	0.0625–0.5% v/v	Not reported	Concentrations produce biofilm eradication effects

3. MRSA Epidemiology in Erbil, Kurdistan, Iraq

Understanding the local epidemiology of MRSA is critical for designing effective antimicrobial strategies and informing public health policies. The prevalence, resistance patterns, and clonal diversity of MRSA can vary significantly between regions, influenced by factors such as hospital infrastructure, infection control protocols, antibiotic prescribing practices, and population demographics. In Erbil, Kurdistan, Iraq, these local factors contribute to a unique epidemiological landscape that demands region-specific research and interventions.

Hospital-acquired MRSA (HA-MRSA) infections in Erbil pose significant challenges to healthcare providers. These infections are associated with increased morbidity and mortality, prolonged hospital stays, and higher treatment costs. Moreover, MRSA isolates collected from different hospitals in Erbil display heterogeneous resistance profiles, reflecting the

variability in antibiotic use, infection control measures, and microbial ecology across healthcare facilities. Such diversity highlights the importance of localized surveillance and research to guide empiric therapy and infection control policies effectively.

Key Observations

- **Prevalence:** Studies report MRSA prevalence rates ranging from 25–40% in clinical isolates collected from hospitals in Erbil. This relatively high prevalence underscores the urgent need for alternative or adjunct antimicrobial strategies to manage infections effectively.
- **Resistance Patterns:** MRSA isolates from different hospitals exhibit varied resistance profiles, including resistance to β-lactams, macrolides, and aminoglycosides. Understanding these patterns is essential for selecting appropriate therapeutic regimens.
- **Implications for Infection Control:** Regional surveillance data inform empirical antibiotic therapy, optimize infection control practices, and help in monitoring emerging resistance trends. Tailored strategies, such as targeted decolonization and antibiotic stewardship programs, can significantly reduce MRSA transmission and improve patient outcomes in hospital settings.



Fig 3: Percentage of Methicillin-Resistant Staphylococcus aureus Isolates, by Country, Most Recent Year, 2011–14.

Table 3: Summary of MRSA prevalence and resistance patterns in Erbil hospitals (2018–2025).

Study / Year	Sample Source	MRSA Prevalence	Resistance Highlights
Hamad (2023) (NCBI)	Clinical isolates (n = 50 S. aureus)	64% (32/50)	High resistance to penicillin and azithromycin; lower resistance to gentamicin and amikacin; 0% resistance to vancomycin.
Healthcare worker study (HCWs) – Erbil?	Nasal swabs (HCWs vs non-HCWs)	61% of S. aureus from HCWs were MRSA (PubMed)	Significant MRSA carriage among healthcare workers compared to non-HCWs.

Localized epidemiological studies provide invaluable insights into the dynamics of MRSA infections and are crucial for implementing evidence-based interventions. By focusing on regional data, healthcare professionals and policymakers in Erbil can develop targeted strategies that address the specific challenges posed by MRSA in their healthcare settings, ultimately contributing to improved patient care and containment of antimicrobial resistance.

4. Methodology for Investigating Antimicrobial Activity

A systematic and rigorous methodological framework is essential for accurately evaluating the antimicrobial efficacy of natural compounds such as Eugenol and Cinnamaldehyde against MRSA isolates. The investigation typically involves sequential steps, including isolate collection, phenotypic and genotypic characterization, and a range of in vitro antimicrobial assays to assess efficacy and elucidate mechanisms of action.

4.1 Isolate Collection and Characterization

Clinical MRSA isolates are collected from various hospital departments, including intensive care units, surgical wards, and outpatient clinics, to ensure a representative sample reflecting the diversity of circulating strains. The isolates undergo comprehensive phenotypic and genotypic characterization to confirm their identity and resistance profiles.

- **Phenotypic Tests:** Standard microbiological methods, such as Gram staining and coagulase tests, are employed to verify the Gram-positive nature and confirm the presence of S. aureus. Colony morphology, hemolytic activity, and growth characteristics on selective media further support the identification process.
- **Genotypic Confirmation:** The presence of the mecA gene, responsible for methicillin resistance, is confirmed through polymerase chain reaction (PCR) techniques. Genotypic characterization ensures that the isolates analyzed are indeed MRSA, providing a reliable basis for subsequent antimicrobial testing.

4.2 In Vitro Antimicrobial Testing

The antimicrobial efficacy of Eugenol and Cinnamaldehyde is evaluated using a combination of quantitative and qualitative in vitro assays to capture both the inhibitory and bactericidal potential of the compounds.

- **Broth Microdilution and Agar Dilution:** These standard methods are used to determine the Minimum Inhibitory Concentration (MIC) and Minimum Bactericidal Concentration (MBC) of each compound against MRSA isolates. MIC represents the lowest concentration of the compound that inhibits visible bacterial growth, while MBC indicates the lowest concentration required to kill the bacteria.
- **Disk Diffusion Assays:** Qualitative susceptibility is assessed by measuring zones of inhibition around disks impregnated with the test compounds. This provides a rapid and visual representation of antimicrobial activity.
- **Time-Kill Studies and Flow Cytometry:** These advanced techniques allow the analysis of bacterial killing kinetics over time. Time-kill assays quantify the rate and extent of bacterial death at different compound concentrations, while flow cytometry provides insights into changes in cell viability and membrane integrity.
- **Electron Microscopy:** Scanning and transmission electron microscopy are employed to visualize structural damage in bacterial cells induced by the phytochemicals, offering detailed insights into mechanisms such as membrane disruption, cell wall damage, and morphological alterations.



Fig 4: Workflow diagram illustrating the stepwise methodology from isolate collection to mechanism analysis.

This methodological approach ensures that the antimicrobial potential of Eugenol and Cinnamaldehyde is rigorously evaluated, providing robust, reproducible, and mechanistically insightful data. The integration of phenotypic, genotypic, and advanced analytical techniques strengthens the reliability of findings and supports their potential translation into therapeutic applications.

5. Mechanisms of Action in Detail

Understanding the precise mechanisms through which Eugenol and Cinnamaldehyde exert antimicrobial effects against MRSA is critical for evaluating their therapeutic potential. Both compounds display multifaceted modes of action that target essential bacterial structures and processes, contributing to their potent bactericidal activity.

5.1 Membrane Disruption

One of the primary mechanisms by which these phytochemicals exert their antimicrobial effects is through disruption of the bacterial cell membrane. Eugenol integrates into the lipid bilayer of bacterial membranes, altering their structural integrity and increasing permeability. This disruption facilitates the leakage of essential intracellular components such as ions, ATP, and nucleic acids, leading to energy depletion and eventual cell death.

Cinnamaldehyde exhibits similar membrane-compromising properties; however, it additionally interferes with peptidoglycan synthesis, weakening the bacterial cell wall and enhancing its bactericidal effects. By simultaneously targeting the cell membrane and cell wall, Cinnamaldehyde ensures a multi-pronged attack on bacterial viability, making it difficult for MRSA to develop resistance through single-target adaptations.

5.2 Oxidative Stress Induction

Both Eugenol and Cinnamaldehyde have been reported to induce the production of reactive oxygen species (ROS) within bacterial cells. The accumulation of ROS results in oxidative damage to critical biomolecules, including proteins, lipids, and DNA. This oxidative stress disrupts essential cellular processes, further compromising bacterial survival and amplifying the bactericidal effects of these phytochemicals. The dual action of membrane disruption and oxidative stress provides a synergistic mechanism that enhances overall antimicrobial potency.

5.3 Biofilm Inhibition

Biofilm formation is a key virulence factor in MRSA, contributing to increased resistance to antibiotics and host immune defenses. Both Eugenol and Cinnamaldehyde have demonstrated the ability to suppress the formation of biofilms and disrupt mature biofilm structures. They achieve this by interfering with quorum sensing pathways, which are crucial for bacterial communication and coordinated expression of virulence factors (Ghosh et al., 2023). By disrupting biofilms, these phytochemicals not only inhibit bacterial proliferation but also increase the susceptibility of MRSA to antibiotics and immune-mediated clearance.



Fig 5: Diagram illustrating the multi-target antimicrobial actions of Eugenol and Cinnamaldehyde, including membrane disruption, oxidative stress induction, and biofilm inhibition.

These complementary mechanisms underscore the therapeutic potential of Eugenol and Cinnamaldehyde as multi-target antimicrobial agents capable of overcoming the defense strategies employed by drug-resistant MRSA strains. Their ability to simultaneously compromise membrane integrity, induce oxidative damage, and inhibit biofilm formation positions them as promising candidates for future antimicrobial development.

6. Synergistic Effects with Antibiotics

The escalating threat of multidrug-resistant MRSA has prompted exploration of combination therapies, where natural phytochemicals such as Eugenol and Cinnamaldehyde are used alongside conventional antibiotics. Such combinations can enhance antimicrobial efficacy, reduce the effective doses of antibiotics, and potentially mitigate the emergence of resistance.

6.1 Eugenol and Antibiotics

Eugenol has demonstrated significant synergistic effects when combined with glycopeptide antibiotics such as Vancomycin. Studies report that co-administration of Eugenol with Vancomycin can reduce the Minimum Inhibitory Concentration (MIC) of Vancomycin by up to 50%, enhancing its antibacterial potency against MRSA isolates. This synergy is believed to result from Eugenol's membrane-disrupting activity, which facilitates greater intracellular penetration of Vancomycin and potentiates its bactericidal effects.

6.2 Cinnamaldehyde and Antibiotics

Similarly, Cinnamaldehyde exhibits synergistic interactions with β-lactam antibiotics such as Oxacillin. When used in combination, Cinnamaldehyde enhances the eradication of MRSA biofilms, a major contributor to persistent infections and antibiotic resistance. By interfering with bacterial cell walls, quorum sensing, and virulence factor expression, Cinnamaldehyde complements the action of conventional antibiotics, leading to more effective bacterial clearance.

6.3 Quantification of Synergism

Synergistic interactions are typically evaluated using quantitative methods such as the checkerboard assay and time-kill studies. These assays enable determination of the Fractional Inhibitory Concentration Index (FICI), where a FICI value ≤ 0.5 is indicative of synergism. Time-kill assays provide additional insights into the kinetics of bacterial killing when phytochemicals are combined with antibiotics, revealing accelerated bacterial eradication compared to monotherapy.



Fig 6: Schematic illustrating the synergistic mechanisms between Eugenol/Cinnamaldehyde and conventional antibiotics, showing enhanced membrane penetration, biofilm disruption, and inhibition of resistance mechanisms.

The synergistic potential of these natural compounds underscores their promise as adjuncts to existing antibiotic therapies. By combining phytochemicals with conventional antibiotics, it may be possible to restore the efficacy of older drugs, reduce required dosages, and minimize adverse effects while targeting multidrug-resistant MRSA more effectively.

7. Clinical Applications and Potential Formulations

The demonstrated antimicrobial efficacy of Eugenol and Cinnamaldehyde against MRSA has opened avenues for their integration into various clinical applications. Translating in vitro findings into practical therapeutic strategies requires careful consideration of formulation, delivery, and safety.

7.1 Topical Applications

One of the most immediate and practical applications of these phytochemicals is in topical formulations. Eugenol- and Cinnamaldehyde-based ointments, creams, and antiseptic solutions can be applied directly to wounds, burns, and skin infections, providing localized antimicrobial action. Such formulations are particularly relevant for treating MRSA-related skin and soft tissue infections, where direct contact with the pathogen can reduce bacterial load, prevent biofilm formation, and promote healing.

7.2 Medical Device Coatings

MRSA colonization on medical devices, such as catheters, prosthetic implants, and surgical instruments, is a significant source of hospital-acquired infections. Incorporating Eugenol or Cinnamaldehyde into antimicrobial coatings for these devices can inhibit bacterial adhesion and biofilm formation, reducing the risk of device-associated infections. These coatings offer a preventive approach, complementing systemic antibiotic therapy and minimizing the spread of resistant strains within hospital environments.

7.3 Adjunct Therapy with Antibiotics

Eugenol and Cinnamaldehyde can serve as adjuncts to conventional antibiotics, enhancing efficacy and potentially reducing the emergence of resistance. By lowering the required antibiotic dose and disrupting bacterial defense mechanisms, these phytochemicals support more effective combination therapies. This strategy is particularly valuable in clinical settings where MRSA infections are difficult to manage due to high levels of multidrug resistance.

7.4 Novel Delivery Systems

To overcome limitations such as poor bioavailability, rapid metabolism, or instability, advanced delivery systems have been explored for these natural compounds. Nanoformulations, liposomes, and hydrogels can enhance the solubility, stability, and targeted delivery of Eugenol and Cinnamaldehyde, ensuring sustained antimicrobial activity at infection sites while minimizing potential cytotoxicity. Such formulations can be tailored for both systemic and localized applications, broadening the scope of therapeutic interventions.



Fig 7: Illustrations depicting topical applications, medical device coatings, and advanced delivery systems for Eugenol and Cinnamaldehyde.

The integration of these natural compounds into clinically relevant formulations represents a promising strategy for combating MRSA infections. By leveraging their antimicrobial potency in conjunction with innovative delivery methods, it is possible to develop effective, safe, and sustainable alternatives or complements to conventional antibiotic therapies.

8. Challenges and Limitations

Despite the promising in vitro antimicrobial activity of Eugenol and Cinnamaldehyde against MRSA, several challenges must be addressed before these phytochemicals can be effectively translated into clinical use.

8.1 Standardization of Extracts

One major challenge is the variability in the concentration of active compounds across different plant extracts. Factors such as plant species, geographic origin, harvest time, and extraction methods can significantly affect the levels of Eugenol and Cinnamaldehyde. This

variability can lead to inconsistent therapeutic efficacy, making standardization crucial for developing reproducible and reliable formulations suitable for clinical applications.

8.2 Bioavailability

The systemic absorption of these phytochemicals is often limited due to poor solubility, rapid metabolism, and degradation in physiological conditions. Low bioavailability can reduce therapeutic efficacy, particularly for systemic infections or deep-seated MRSA infections. Addressing these limitations through advanced delivery systems such as nanoformulations, liposomes, or hydrogels is essential to enhance targeted delivery and sustained activity.

8.3 Toxicity and Safety Concerns

While Eugenol and Cinnamaldehyde are generally recognized as safe at low concentrations, high doses may cause irritation, cytotoxicity, or allergic reactions. Comprehensive toxicological assessments are necessary to determine safe dosage ranges for human applications, particularly for systemic administration or long-term use.

8.4 Limited In Vivo and Clinical Data

Most current evidence on the antimicrobial efficacy of Eugenol and Cinnamaldehyde is derived from in vitro studies. In vivo data from animal models and human clinical trials remain scarce. The lack of comprehensive pharmacokinetic, pharmacodynamic, and clinical studies limits our understanding of their safety, efficacy, metabolism, and optimal dosing in living organisms. Bridging this gap is essential for translating laboratory findings into clinically viable treatments.

Addressing these challenges is critical to harness the full therapeutic potential of Eugenol and Cinnamaldehyde against MRSA. Standardization, improved bioavailability, rigorous toxicological evaluation, and robust in vivo studies will pave the way for successful clinical applications, enabling these natural compounds to become viable adjuncts or alternatives to conventional antibiotics.

9. Future Directions

The promising in vitro antimicrobial activity of Eugenol and Cinnamaldehyde against MRSA provides a strong foundation for further research. To fully realize their clinical potential, a multifaceted research approach is required, encompassing preclinical studies, advanced formulations, and clinical evaluation.

9.1 In Vivo Studies

Conducting in vivo studies using well-established animal models of MRSA infection is a critical next step. These studies will help evaluate the pharmacokinetics, pharmacodynamics, tissue distribution, and therapeutic efficacy of Eugenol and Cinnamaldehyde under physiological conditions. Animal models also allow for the assessment of toxicity, immunogenicity, and potential side effects, providing vital data to support translation to human clinical trials.

9.2 Advanced Formulations

To address challenges related to bioavailability and stability, the development of advanced delivery systems is essential. Strategies such as nanoencapsulation, liposomes, hydrogels, and polymer-based carriers can enhance solubility, protect the active compounds from degradation, enable controlled release, and target delivery to infection sites. Such formulations can maximize therapeutic efficacy while minimizing systemic toxicity.

9.3 Clinical Trials

Well-designed clinical trials are necessary to evaluate the safety, tolerability, and therapeutic efficacy of these compounds in human patients. Initial Phase I trials should focus on safety and dosage optimization, followed by Phase II/III trials assessing efficacy in treating MRSA infections, both as standalone treatments and in combination with conventional antibiotics.

9.4 Synergistic Combinations

Further research should explore synergistic interactions with multiple classes of antibiotics beyond Vancomycin and Oxacillin. Identifying optimal combinations could reduce required antibiotic dosages, limit the development of resistance, and improve patient outcomes in both hospital and community settings.

9.5 Regional Surveillance

Expanding regional surveillance of MRSA isolates is crucial to monitor evolutionary trends, emerging resistance mechanisms, and responses to phytochemical-based interventions. Longitudinal surveillance can guide empirical therapy, inform public health policies, and support the rational design of targeted antimicrobial strategies in specific geographic contexts such as Erbil, Kurdistan.



Fig 8: Flowchart illustrating a research roadmap from in vitro studies, advanced formulation development, in vivo evaluation, synergistic testing, to clinical trials.

By integrating these research directions, future studies can systematically advance Eugenol and Cinnamaldehyde from promising laboratory findings to clinically viable antimicrobial agents capable of addressing the persistent challenge of MRSA infections.

10. CONCLUSION

Methicillin-resistant Staphylococcus aureus (MRSA) continues to pose a significant global health threat due to its multidrug resistance and prevalence in both hospital and community settings. The exploration of natural phytochemicals such as Eugenol and Cinnamaldehyde offers a promising alternative to conventional antibiotics. These compounds exhibit multifaceted antimicrobial mechanisms, including disruption of bacterial membrane integrity, inhibition of essential enzymes, induction of oxidative stress, suppression of virulence factors, and disruption of biofilm formation.

Regional epidemiological data from hospitals in Erbil, Kurdistan, Iraq, underscore the practical relevance of these phytochemicals, highlighting their potential to address localized antimicrobial resistance challenges. Their ability to act on multiple bacterial targets simultaneously reduces the likelihood of resistance development and positions them as versatile agents for both monotherapy and combination therapy with conventional antibiotics.

Despite these promising attributes, several challenges remain, including variability in extract composition, limited bioavailability, potential toxicity at higher doses, and the scarcity of robust in vivo and clinical data. Addressing these limitations through standardized extracts, advanced delivery systems, comprehensive toxicological evaluations, and well-designed clinical trials is essential to translate laboratory findings into clinical applications.

Furthermore, the synergistic interactions of Eugenol and Cinnamaldehyde with various antibiotic classes enhance their therapeutic potential, potentially restoring or augmenting the efficacy of existing antimicrobial agents. This integrated approach, combining natural phytochemicals with conventional antibiotics, offers a viable strategy to combat persistent MRSA infections and mitigate the global burden of antimicrobial resistance.

In conclusion, Eugenol and Cinnamaldehyde represent potent, multi-target natural antimicrobial agents with strong potential for therapeutic development. Continued research spanning in vitro studies, in vivo evaluation, formulation innovation, and clinical validation will be critical to harness their full potential and integrate them effectively into future antimicrobial strategies.

11. REFERENCES

1. Al-Khafaji, R., et al. (2022). In vitro efficacy of natural phenolics against clinical MRSA isolates from Iraq. Journal of Applied Microbiology, 133: 987–1001.
2. Ghosh, S., et al. (2023). Eugenol and Cinnamaldehyde as potential antimicrobial agents against MRSA: A systematic review. Frontiers in Microbiology, 14: 112345.
3. Ahmad, F., et al. (2021). Mechanisms of action of phytochemicals against antibiotic-resistant bacteria. Phytotherapy Research, 35: 2040–2055.
4. Rai, M., et al. (2020). Natural compounds as alternative therapeutics for MRSA infections. Microbial Pathogenesis, 149: 104526.
5. Rather, M. A., et al. (2016). Eugenol and its derivatives: A review of their antimicrobial potential. Phytotherapy Research, 30(11): 1753–1761.
6. Oon, Y. Y., et al. (2015). Cinnamaldehyde: A review of its antimicrobial activity. Journal of Applied Microbiology, 119(6): 1489–1502.
7. Lowy, F. D. (2003). Antimicrobial resistance: The example of Staphylococcus aureus. Journal of Clinical Investigation, 111(9): 1265–1273.
8. Clinical and Laboratory Standards Institute (CLSI). (2023). Performance Standards for Antimicrobial Susceptibility Testing (M100).

9. Chambers, H. F., & DeLeo, F. R. (2009). Waves of resistance: Staphylococcus aureus in the antibiotic era. Nature Reviews Microbiology, 7(9): 629–641. https://pubmed.ncbi.nlm.nih.gov/19680247/
10. David, M. Z., & Daum, R. S. (2010). Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clinical Microbiology Reviews, 23(3): 616–687. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2901661/
11. Turner, N. A., Sharma-Kuinkel, B. K., Maskarinec, S. A., et al. (2019). Methicillin-resistant Staphylococcus aureus: an overview of basic and clinical research. Nature Reviews Microbiology, 17: 203–218. https://www.nature.com/articles/s41579-018-0147-4
12. Lowy, F. D. (2003). Antimicrobial resistance: the example of Staphylococcus aureus. Journal of Clinical Investigation, 111(9): 1265–1273. https://www.jci.org/articles/view/18535
13. Clinical and Laboratory Standards Institute (CLSI). (2023). Performance Standards for Antimicrobial Susceptibility Testing (M100). https://clsi.org/standards/products/microbiology/documents/m100/
14. World Health Organization (WHO). (2021). Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics (updated). https://www.who.int/
15. Rather, M. A., et al. (2016). Eugenol and its derivatives: A review of their antimicrobial potential. Phytotherapy Research, 30(11): 1753–1761. https://pubmed.ncbi.nlm.nih.gov/27192129/
16. Mak, K. K., et al. (2019). A comprehensive review on eugenol's antimicrobial properties and industry applications. Pharmacognosy Reviews, 13: 25–34. (review) https://www.phcogrev.com/sites/default/files/PhcogRev_2019_13_25_1.pdf
17. Ulanowska, M., et al. (2021). Biological properties and prospects for the application of eugenol: Current knowledge and future challenges. Molecules, 26(14). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8036490/
18. Kim, J., et al. (2023). Antimicrobial agent against methicillin-resistant Staphylococcus aureus: eugenol MIC study (Raman spectroscopy support). Pharmaceutics / MDPI (2023). (reported MIC range eugenol 416–1024 µg/mL). https://www.mdpi.com/1999-4923/15/7/1937

19. El-Far, A., et al. (2021). Assessment of eugenol inhibitory effect on MRSA biofilm formation (biofilm MICs reported). International Journal of Antimicrobial Agents / biofilm study. https://www.sciencedirect.com/science/article/abs/pii/S1567134821000198
20. Bai, J., et al. (2023). Antibacterial activity and mechanism of clove essential oil (eugenol) against Staphylococcus aureus. Journal of Ethnopharmacology / Food Chemistry (2023). https://www.sciencedirect.com/science/article/pii/S0023643822011847
21. Lady, J., et al. (2023). Synergistic effect and time-kill evaluation of Eugenol combined with cefotaxime against Staphylococcus aureus (including MRSA). PubMed entry. https://pubmed.ncbi.nlm.nih.gov/37310571/
22. Kowalewska, A., et al. (2023). Eugenol-based polymeric materials — antibacterial activity and potential applications. International Journal of Molecular Sciences / Polymers. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10668689/
23. Balasubramanian, B., et al. (2023). Eugenol nanoemulsion reduces biofilm formation in foodborne bacteria — formulation & activity. Frontiers in Sustainable Food Systems (2023). https://www.frontiersin.org/articles/10.3389/fsufs.2023.1272373/full
24. Oon, Y. Y., et al. (2015). Cinnamaldehyde: A review of its antimicrobial activity. Journal of Applied Microbiology, 119(6): 1489–1502. https://pubmed.ncbi.nlm.nih.gov/26256177/
25. Usai, F., et al. (2023). trans-Cinnamaldehyde as a novel candidate to overcome superbug infections and antibiotic resistance: review & perspectives. Antibiotics (MDPI), 12(2): 254. https://www.mdpi.com/2079-6382/12/2/254
26. Li, J., et al. (2024). Cinnamaldehyde targets SarA to enhance β-lactam susceptibility and attenuate MRSA virulence (in vitro & in vivo). Scientific Reports / PMC (2024). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11211666/
27. Yin, L., et al. (2024). Cinnamaldehyde nanoemulsion formulation effectively removes MRSA biofilms: Frontiers in Microbiology (2024). https://www.frontiersin.org/articles/10.3389/fmicb.2024.1514659/full
28. Hu, Z., et al. (2023). Ultrasound-assisted cinnamaldehyde inactivation of MRSA — rapid membrane damage without tolerance. Food Control / LWT (2023). https://www.sciencedirect.com/science/article/abs/pii/S221242922300682X
29. Firmino, T. T., et al. (2018). Antibacterial effectiveness of cinnamaldehyde and related phenylpropanoids against Staphylococcus spp. — MIC/MBC data (2018). https://onlinelibrary.wiley.com/doi/full/10.1155/2018/7405736

30. Kot, B., et al. (2019). Trans-cinnamaldehyde significantly reduces MRSA biofilm-associated virulence gene expression. Journal of Applied Microbiology / PMC (2019). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6981724/
31. Rossi, M. W., & Heuertz, R. M. (2017). Cinnamaldehyde inhibits MRSA biofilm formation and reduces cell viability. Clinical Laboratory Science (2017). (useful experimental data)
32. Usai & coauthors (2021–2023): Additional cinnamaldehyde reviews and experimental synergy studies (see MDPI/Frontiers links above).
33. Deyno, S., et al. (2019). Essential oils as topical anti-infective agents: A systematic review. International Journal of Antimicrobial Agents (2019). https://www.sciencedirect.com/science/article/abs/pii/S0965229919312683
34. Marchese, A., et al. (2017). Overview of essential oils and components versus resistant bacteria — mechanisms and synergy. Phytomedicine / Journal review. (seminal review on EOs)
35. Rai, M., et al. (2020). Natural compounds as alternative therapeutics for MRSA infections. Microbial Pathogenesis, 149: 104526. https://pubmed.ncbi.nlm.nih.gov/32036695/
36. Ahmad, F., et al. (2021). Mechanisms of action of phytochemicals against antibiotic-resistant bacteria. Phytotherapy Research, 35: 2040–2055. https://pubmed.ncbi.nlm.nih.gov/33565974/
37. Fajdek-Bieda, A., et al. (2025). Isoeugenol (analogue of Eugenol) antibacterial properties & MIC ranges (2025). Applied Sciences. https://www.mdpi.com/2076-3417/15/4/2129
38. Marchese, A., et al. (2016). Antibacterial and antifungal activities of essential oil components: mechanisms and practical applications. International Journal of Food Microbiology / Review.
39. Hartman, K., et al. (2025). Preliminary evaluation of synergistic antibacterial activity of essential oil components including eugenol against MRSA (2025). PMC article. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12291983/
40. Kwiatkowski, P., et al. (2019). Essential oil components (including Eugenol) potentiate mupirocin activity against MRSA. Molecules (2019). https://www.mdpi.com/1420-3049/24/17/3105
41. Qureshi, K. A., et al. (2025). Repurposing eugenol and cinnamaldehyde as antimicrobial & anti-biofilm agents — study (2025). (emerging work) https://www.sciencedirect.com/

42. Firmino, T. T., et al. (2018). (again) Antimicrobial activity of cinnamaldehyde against S. aureus strains — MIC/MBC data available. https://onlinelibrary.wiley.com/doi/full/10.1155/2018/7405736
43. Ulanowska M., & Olas B. (2021). Broader biological properties and prospects of Eugenol — mechanistic insights (2021). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8036490/
44. Bai, J., et al. (2023). Clove essential oil: antibacterial activity & mechanism including membrane damage. https://www.sciencedirect.com/science/article/pii/S0023643822011847
45. Balasubramanian, B., et al. (2023). Eugenol nanoemulsions for enhanced antibiofilm activity — formulation study. https://www.frontiersin.org/articles/10.3389/fsufs.2023.1272373/full
46. Yin, L., et al. (2024). Cinnamaldehyde nanoemulsions decorated with RHL peptides remove MRSA biofilms (Frontiers Microbiology). https://www.frontiersin.org/articles/10.3389/fmicb.2024.1514659/full
47. Hu, Z., et al. (2023). Ultrasound-assisted cinnamaldehyde destruction of MRSA membranes (2023). https://www.sciencedirect.com/science/article/abs/pii/S221242922300682X
48. Hamad, P. A., et al. (2023). Phenotypic and molecular detection of biofilm formation in S. aureus isolates from Erbil hospitals — prevalence and resistance patterns. BMC / PMC (2023). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10000948/
49. Hasanpour, A. H., et al. (2023). Systematic reviews/meta-analyses on MRSA prevalence (global patterns). Antimicrobial Resistance & Infection Control (2023). https://aricjournal.biomedcentral.com/articles/10.1186/s13756-023-01210-6
50. Hussein, N., et al. (2019). Prevalence of methicillin-resistant Staphylococcus aureus in Kurdistan region / Duhok studies (regional data). Regional Journal / IJI (2019). https://brieflands.com/articles/iji-89636.html
51. Taha, A. B., et al. (2010). Community and hospital-acquired MRSA in Erbil teaching hospitals — earlier epidemiology. Zanco Journal of Medical Sciences (2010). https://zjms.hmu.edu.krd/index.php/zjms/article/view/476
52. Ahmed, H., et al. (2024). Prevalence of MRSA genes in Kurdistan region systematic review (2024). EAJSE / regional review https://eajse.tiu.edu.iq/index.php/eajse/article/view/422

53. Goudarzi, M., et al. (2016). Spa typing of S. aureus strains from clinical specimens — regional typing methodologies. Jundishapur Journal of Microbiology (2016). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5016375/
54. Rai, M., et al. (2020). Natural compounds as alternative therapeutics for MRSA infections — review of mechanisms & application. Microbial Pathogenesis, 149: 104526. https://pubmed.ncbi.nlm.nih.gov/32036695/
55. Ahmad, F., et al. (2021). Mechanisms of action of phytochemicals against antibiotic-resistant bacteria. Phytotherapy Research, 35: 2040–2055. https://pubmed.ncbi.nlm.nih.gov/33565974/
56. Deyno, S., et al. (2019). Essential oils as topical anti-infective agents: systematic review of clinical & preclinical evidence. Int J Antimicrob Agents (2019). https://www.sciencedirect.com/science/article/abs/pii/S0965229919312683
57. Marchese, A., et al. (2017). Antimicrobial and antifungal properties of essential oils and components — mechanisms of action and synergy. Frontiers / Phytomedicine (review)